Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Radius Health (RDUS) Trades to Session Lows
October 12, 2015 2:41 PM EDTRadius Health (Nasdaq: RDUS) is moving to session lows Monday after the company announced the... More
Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover Plays
October 12, 2015 12:06 PM EDTRadius Health (NASDAQ: RDUS) and Dyax Corp (NASDAQ: DYAX) highlighted as a potential takeover targets on... More
Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation
October 12, 2015 9:10 AM EDTCanaccord Genuity reiterated a Buy rating and $85.00 price target on Radius Health (NASDAQ: RDUS) after presenting new transdermal data at ASBMR.
Analyst John Newman commented, "Radius presented new transdermal data at ASBMR in monkeys, which increased AUC ~2x versus the original patch,... More
Radius Health (RDUS) Presents Positive Phase 3 Data from ACTIVE Trial at ASBMR Meeting
October 12, 2015 6:51 AM EDTRadius Health, Inc. (Nasdaq: RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial InVertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo. Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, along with positive pharmacokinetic data from a study evaluating the ABL... More
